Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
5.57
-0.16 (-2.79%)
At close: Jul 23, 2025, 4:00 PM
5.65
+0.08 (1.44%)
After-hours: Jul 23, 2025, 7:22 PM EDT

Company Description

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.

The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release.

Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders.

Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc.
Cingulate logo
CountryUnited States
Founded2012
IPO DateDec 8, 2021
IndustryBiotechnology
SectorHealthcare
Employees13
CEOShane Schaffer

Contact Details

Address:
1901 West 47th Place
Kansas City, Kansas 66205
United States
Phone913 942 2300
Websitecingulate.com

Stock Details

Ticker SymbolCING
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$6.00
CIK Code0001862150
CUSIP Number17248W105
ISIN NumberUS17248W3034
Employer ID86-3825535
SIC Code2834

Key Executives

NamePosition
Dr. Shane J. Schaffer Pharm.D.Co-Founder, Chief Executive Officer and Chairman of the Board
Jennifer L. Callahan CPASenior Vice President, Chief Financial Officer and Secretary
Dr. Laurie A. Myers M.B.A., Ph.D.Executive Vice President and Chief Operating Officer
Dr. Raul R. Silva M.D.Co-Founder, Executive Vice President and Chief Science Officer
Dr. Matthew N. Brams M.D.Co-Founder, Executive Vice President and Chief Medical Officer
Thomas DaltonVice President of Investor and Public Relations

Latest SEC Filings

DateTypeTitle
Jul 22, 2025S-1General form for registration of securities under the Securities Act of 1933
Jul 22, 20258-KCurrent Report
Jun 11, 20258-KCurrent Report
May 13, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 28, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025ARSFiling
Apr 25, 2025DEF 14AOther definitive proxy statements
Apr 15, 2025PRE 14AOther preliminary proxy statements